OpenAccessBelV2, PascalFrancis, Corpus, bibRecord, 000077

Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column

Identifieur interne : 000077 ( PascalFrancis/Corpus ); précédent : 000076; suivant : 000078

Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column

Auteurs : Claudio Brunelli ; YINING ZHAO ; Melissa-Hanna Brown ; Pat Sandra

Source :

Journal of separation science [ 1615-9306 ] ; 2008.

RBID : Pascal:08-0393504

Descripteurs français

Pascal (Inist)
- Analyse chimique, Médicament, Chromatographie SFC, Optimisation, Phase stationnaire, Phase mobile, Composition phase, Composition phase mobile, Pyridine(2-éthyl).

English descriptors

KwdEn :
- Chemical analysis, Drug, Mobile phase, Optimization, Phase composition, Stationary phase, Supercritical fluid chromatography.

Abstract

The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1615-9306`
A03		`1`		`@0 J. sep. sci. : (print)`
A05				`@2 31`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column`
A09	`01`	`1`	`ENG`	`@1 Supercritical fluids in separation science`
A11	`01`	`1`		`@1 BRUNELLI (Claudio)`
A11	`02`	`1`		`@1 YINING ZHAO`
A11	`03`	`1`		`@1 BROWN (Melissa-Hanna)`
A11	`04`	`1`		`@1 SANDRA (Pat)`
A14	`01`			`@1 Pfizer Analytical Research Centre, Ghent University @2 Ghent @3 BEL @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Analytical R&D, Pfizer Global R&D @2 Groton, CT @3 USA @Z 2 aut.`
A14	`03`			`@1 Pfizer Global R&D, Analytical R&D @2 Sandwich, Kent @3 GBR @Z 3 aut.`
A20				`@1 1299-1306`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17941 @5 354000195931290080`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 08-0393504`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of separation science`
A66	`01`			`@0 DEU`
C01	`01`		`ENG`	@0 The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.
C02	`01`	`X`		`@0 002B02A02`
C03	`01`	`X`	`FRE`	`@0 Analyse chimique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemical analysis @5 01`
C03	`01`	`X`	`SPA`	`@0 Análisis químico @5 01`
C03	`02`	`X`	`FRE`	`@0 Médicament @5 02`
C03	`02`	`X`	`ENG`	`@0 Drug @5 02`
C03	`02`	`X`	`SPA`	`@0 Medicamento @5 02`
C03	`03`	`X`	`FRE`	`@0 Chromatographie SFC @5 03`
C03	`03`	`X`	`ENG`	`@0 Supercritical fluid chromatography @5 03`
C03	`03`	`X`	`SPA`	`@0 Cromatografia fluido supercritico @5 03`
C03	`04`	`X`	`FRE`	`@0 Optimisation @5 04`
C03	`04`	`X`	`ENG`	`@0 Optimization @5 04`
C03	`04`	`X`	`SPA`	`@0 Optimización @5 04`
C03	`05`	`X`	`FRE`	`@0 Phase stationnaire @5 06`
C03	`05`	`X`	`ENG`	`@0 Stationary phase @5 06`
C03	`05`	`X`	`SPA`	`@0 Fase estacionaria @5 06`
C03	`06`	`X`	`FRE`	`@0 Phase mobile @5 07`
C03	`06`	`X`	`ENG`	`@0 Mobile phase @5 07`
C03	`06`	`X`	`SPA`	`@0 Fase móvil @5 07`
C03	`07`	`X`	`FRE`	`@0 Composition phase @5 32`
C03	`07`	`X`	`ENG`	`@0 Phase composition @5 32`
C03	`07`	`X`	`SPA`	`@0 Composición fase @5 32`
C03	`08`	`X`	`FRE`	`@0 Composition phase mobile @4 INC @5 76`
C03	`09`	`X`	`FRE`	`@0 Pyridine(2-éthyl) @2 NK @4 INC @5 77`
N21				`@1 252`

Format Inist (serveur)

NO :	PASCAL 08-0393504 INIST
ET :	Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column
AU :	BRUNELLI (Claudio); YINING ZHAO; BROWN (Melissa-Hanna); SANDRA (Pat)
AF :	Pfizer Analytical Research Centre, Ghent University/Ghent/Belgique (1 aut., 4 aut.); Analytical R&D, Pfizer Global R&D/Groton, CT/Etats-Unis (2 aut.); Pfizer Global R&D, Analytical R&D/Sandwich, Kent/Royaume-Uni (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of separation science; ISSN 1615-9306; Allemagne; Da. 2008; Vol. 31; No. 8; Pp. 1299-1306; Bibl. 16 ref.
LA :	Anglais
EA :	The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.
CC :	002B02A02
FD :	Analyse chimique; Médicament; Chromatographie SFC; Optimisation; Phase stationnaire; Phase mobile; Composition phase; Composition phase mobile; Pyridine(2-éthyl)
ED :	Chemical analysis; Drug; Supercritical fluid chromatography; Optimization; Stationary phase; Mobile phase; Phase composition
SD :	Análisis químico; Medicamento; Cromatografia fluido supercritico; Optimización; Fase estacionaria; Fase móvil; Composición fase
LO :	INIST-17941.354000195931290080
ID :	08-0393504

Links to Exploration step

Pascal:08-0393504

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column</title>
<author><name sortKey="Brunelli, Claudio" sort="Brunelli, Claudio" uniqKey="Brunelli C" first="Claudio" last="Brunelli">Claudio Brunelli</name>
<affiliation><inist:fA14 i1="01"><s1>Pfizer Analytical Research Centre, Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yining Zhao" sort="Yining Zhao" uniqKey="Yining Zhao" last="Yining Zhao">YINING ZHAO</name>
<affiliation><inist:fA14 i1="02"><s1>Analytical R&D, Pfizer Global R&D</s1>
<s2>Groton, CT</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Melissa Hanna" sort="Brown, Melissa Hanna" uniqKey="Brown M" first="Melissa-Hanna" last="Brown">Melissa-Hanna Brown</name>
<affiliation><inist:fA14 i1="03"><s1>Pfizer Global R&D, Analytical R&D</s1>
<s2>Sandwich, Kent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sandra, Pat" sort="Sandra, Pat" uniqKey="Sandra P" first="Pat" last="Sandra">Pat Sandra</name>
<affiliation><inist:fA14 i1="01"><s1>Pfizer Analytical Research Centre, Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0393504</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0393504 INIST</idno>
<idno type="RBID">Pascal:08-0393504</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000077</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column</title>
<author><name sortKey="Brunelli, Claudio" sort="Brunelli, Claudio" uniqKey="Brunelli C" first="Claudio" last="Brunelli">Claudio Brunelli</name>
<affiliation><inist:fA14 i1="01"><s1>Pfizer Analytical Research Centre, Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yining Zhao" sort="Yining Zhao" uniqKey="Yining Zhao" last="Yining Zhao">YINING ZHAO</name>
<affiliation><inist:fA14 i1="02"><s1>Analytical R&D, Pfizer Global R&D</s1>
<s2>Groton, CT</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brown, Melissa Hanna" sort="Brown, Melissa Hanna" uniqKey="Brown M" first="Melissa-Hanna" last="Brown">Melissa-Hanna Brown</name>
<affiliation><inist:fA14 i1="03"><s1>Pfizer Global R&D, Analytical R&D</s1>
<s2>Sandwich, Kent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sandra, Pat" sort="Sandra, Pat" uniqKey="Sandra P" first="Pat" last="Sandra">Pat Sandra</name>
<affiliation><inist:fA14 i1="01"><s1>Pfizer Analytical Research Centre, Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of separation science</title>
<title level="j" type="abbreviated">J. sep. sci. : (print)</title>
<idno type="ISSN">1615-9306</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of separation science</title>
<title level="j" type="abbreviated">J. sep. sci. : (print)</title>
<idno type="ISSN">1615-9306</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemical analysis</term>
<term>Drug</term>
<term>Mobile phase</term>
<term>Optimization</term>
<term>Phase composition</term>
<term>Stationary phase</term>
<term>Supercritical fluid chromatography</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Analyse chimique</term>
<term>Médicament</term>
<term>Chromatographie SFC</term>
<term>Optimisation</term>
<term>Phase stationnaire</term>
<term>Phase mobile</term>
<term>Composition phase</term>
<term>Composition phase mobile</term>
<term>Pyridine(2-éthyl)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1615-9306</s0>
</fA01>
<fA03 i2="1"><s0>J. sep. sci. : (print)</s0>
</fA03>
<fA05><s2>31</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Supercritical fluids in separation science</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>BRUNELLI (Claudio)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YINING ZHAO</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BROWN (Melissa-Hanna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SANDRA (Pat)</s1>
</fA11>
<fA14 i1="01"><s1>Pfizer Analytical Research Centre, Ghent University</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Analytical R&D, Pfizer Global R&D</s1>
<s2>Groton, CT</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Pfizer Global R&D, Analytical R&D</s1>
<s2>Sandwich, Kent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1299-1306</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17941</s2>
<s5>354000195931290080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0393504</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of separation science</s0>
</fA64>
<fA66 i1="01"><s0>DEU</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02A02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Analyse chimique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemical analysis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Análisis químico</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Médicament</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Drug</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chromatographie SFC</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Supercritical fluid chromatography</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Cromatografia fluido supercritico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Optimisation</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Optimization</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Optimización</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Phase stationnaire</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Stationary phase</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Fase estacionaria</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Phase mobile</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Mobile phase</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Fase móvil</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Composition phase</s0>
<s5>32</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Phase composition</s0>
<s5>32</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Composición fase</s0>
<s5>32</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Composition phase mobile</s0>
<s4>INC</s4>
<s5>76</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pyridine(2-éthyl)</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>77</s5>
</fC03>
<fN21><s1>252</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 08-0393504 INIST</NO>
<ET>Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column</ET>
<AU>BRUNELLI (Claudio); YINING ZHAO; BROWN (Melissa-Hanna); SANDRA (Pat)</AU>
<AF>Pfizer Analytical Research Centre, Ghent University/Ghent/Belgique (1 aut., 4 aut.); Analytical R&D, Pfizer Global R&D/Groton, CT/Etats-Unis (2 aut.); Pfizer Global R&D, Analytical R&D/Sandwich, Kent/Royaume-Uni (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of separation science; ISSN 1615-9306; Allemagne; Da. 2008; Vol. 31; No. 8; Pp. 1299-1306; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>The separation of neutral, acidic, and basic pharmaceuticals with diverse physicochemical properties by packed column supercritical fluid chromatography (pSFC) on a 2-ethylpyridine column (25 cm x 4.6 mm id, 3 μm particles) is presented. The optimization strategy involved separations at 100% methanol (MeOH) and at 50% MeOH/50% ACN while keeping the peak symmetry additives formic acid (FA) and isopropylamine (IPA) at constant levels of 0.25% v/v. By plotting the adjusted retention times as a function of the MeOH/ACN ratio, an optimal modifier ratio composition of 65% MeOH/35% ACN was found. The total set of 26 neutral, acidic, and basic pharmaceuticals was analyzed and the optimal composition experimentally verified. This mobile phase composition is currently used in pharmaceutical method development and open-access generic screening environments.</EA>
<CC>002B02A02</CC>
<FD>Analyse chimique; Médicament; Chromatographie SFC; Optimisation; Phase stationnaire; Phase mobile; Composition phase; Composition phase mobile; Pyridine(2-éthyl)</FD>
<ED>Chemical analysis; Drug; Supercritical fluid chromatography; Optimization; Stationary phase; Mobile phase; Phase composition</ED>
<SD>Análisis químico; Medicamento; Cromatografia fluido supercritico; Optimización; Fase estacionaria; Fase móvil; Composición fase</SD>
<LO>INIST-17941.354000195931290080</LO>
<ID>08-0393504</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000077 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000077 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0393504
   |texte=   Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column
}}

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024

	Serveur d'exploration autour du libre accès en Belgique
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour du libre accès en Belgique

Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column

Pharmaceutical analysis by supercritical fluid chromatography : Optimization of the mobile phase composition on a 2-ethylpyridine column

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri